6875.TWO Pharmosa Biopharm Inc.
- Market cap
- TWD 3.26B
- P/E
- -
- P/B
- 2.48x
- ROE
- -28.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6875.TWO undervalued?
Graham numberThe Graham number of Pharmosa Biopharm Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pharmosa Biopharm Inc. fundamental analysis
No fundamental analysis for Pharmosa Biopharm Inc. yet.
Pharmosa Biopharm Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pharmosa Biopharm Inc.
Pharmosa Biopharm Inc., a biotechnology company, focuses on research and development of new drugs in Taiwan. The company develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease, which has completed a Phase I clinical trial. The company was formerly known as Pharmosa Limite…
Full company profilePharmosa Biopharm Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pharmosa Biopharm Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | - | 0.00 | 315M | 168M | 67.3M | 3.58M |
| Gross Profit | - | - | - | 315M | 127M | 13.0M | 660K |
| Operating Income | -178M | -255M | -266M | 11.3M | -219M | -403M | -410M |
| EBITDA | -167M | -243M | -253M | 34.6M | -138M | -350M | -340M |
| Net Income | -182M | -256M | -267M | 8.46M | -167M | -384M | -389M |
| EPS | -3.72 | -2.94 | -2.65 | 0.07 | -1.29 | -2.97 | -3.01 |
| Balance Sheet | |||||||
| Total Assets | 543M | 586M | 799M | 1.33B | 2.16B | 1.75B | 1.78B |
| Total Liabilities | 137M | 54.9M | 38.2M | 196M | 226M | 191M | 417M |
| Shareholders' Equity | 406M | 531M | 761M | 1.14B | 1.94B | 1.56B | 1.37B |
| Cash & Short-term Investments | 415M | 461M | 673M | 974M | 749M | 631M | 733M |
| Total Debt | 124M | 37.1M | 21.2M | 144M | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -181M | -238M | -258M | 42.4M | -127M | -357M | -392M |
| Capital Expenditure | 7.05M | 3.25M | 10.2M | 81.5M | 166M | 119M | 282M |
| Free Cash Flow | -189M | -241M | -268M | -39.0M | -293M | -477M | -674M |
| Ratios | |||||||
| ROE | -44.8% | -48.3% | -35.0% | 0.7% | -8.6% | -24.6% | -28.4% |
| ROA | -33.4% | -43.7% | -33.3% | 0.6% | -7.7% | -22.0% | -21.8% |
| Net Profit Margin | - | - | - | 2.7% | -99.5% | -570.6% | -10,842.5% |
| Debt to Equity | 0.31x | 0.07x | 0.03x | 0.13x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pharmosa Biopharm Inc. dividends
Pharmosa Biopharm Inc. has not paid dividends in the last 7 fiscal years.
Who owns Pharmosa Biopharm Inc.
- Insiders 39.55%
- Institutions 2.08%
- Public & others 58.37%
- Shares outstanding 129M
- Free float 76.3M
Pharmosa Biopharm Inc. company profile
- Company name
- Pharmosa Biopharm Inc.
- Ticker
- 6875.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 508, Section 7, Zhongxiao E. Rd., Taipei, Taiwan
- Phone
- 886 2 2782 7561
- Website
- pharmosa.com.tw
About Pharmosa Biopharm Inc.
Pharmosa Biopharm Inc., a biotechnology company, focuses on research and development of new drugs in Taiwan. The company develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease, which has completed a Phase I clinical trial. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was incorporated in 2000 and is headquartered in Taipei, Taiwan.
Pharmosa Biopharm Inc. management
6- Dr. Pei Kan Ph.D.President, GM & Director
- Mr. Hui-An PaoVice President of Operations
- Ms. Ru-Yun Lin M.B.A.Vice President of Administration · born 1966
- Mr. Wei Shu LuSenior Director of Strategic & Project Development Division
- Mr. Frank LiangSenior Director of Process Development Division
- Ms. Shu-Ping YangVice President of Finance & Accounting